Common Contracts

65 similar Underwriting Agreement contracts by Orthopediatrics Corp, Aziyo Biologics, Inc., Biolase, Inc, others

5,250,000 Shares1 NEUROONE MEDICAL TECHNOLOGIES CORPORATION Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • July 27th, 2023 • NEUROONE MEDICAL TECHNOLOGIES Corp • Surgical & medical instruments & apparatus • New York

NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”) proposes to sell to The Benchmark Company, LLC (the “Underwriter”) an aggregate of 5,250,000 shares (the “Firm Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company has also granted to the Underwriter an option to purchase up to 787,500 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”

AutoNDA by SimpleDocs
6,250,000 Shares Miromatrix Medical Inc. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • March 8th, 2023 • Miromatrix Medical Inc. • Biological products, (no disgnostic substances) • New York
22,225,000 Shares ATYR PHARMA, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • February 9th, 2023 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • New York

aTyr Pharma, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 22,225,000 shares (the “Firm Shares”) of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 3,333,750 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”

FORM OF UNDERWRITING AGREEMENT BIOLASE, INC.
Underwriting Agreement • January 3rd, 2023 • Biolase, Inc • Dental equipment & supplies • New York

Biolase, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters” or each, an “Underwriter”) an aggregate of (x) [•] shares (each a “Firm Share” and collectively, the “Firm Share”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) and (y) [•] pre-funded common stock purchase warrants of the Company (each a “Firm Pre-Funded Warrant” and collectively, the “Firm Pre-Funded Warrants”), with each Firm Pre-Funded Warrant exercisable to purchase one share of Common Stock at an exercise price of $0.01 per share. The Firm Shares and the Firm Pre-Funded Warrants are collectively referred to herein as the “Firm Securities”. The Company also proposes to sell to the Underwriters in any combination, at the option of the Representative, up to an additional (i) [•] shares of Common Stock (the “Option Shares” and, collectively with the Firm Shares, the “Shares”), and (ii) [•] pre-fu

FORM OF UNDERWRITING AGREEMENT BIOLASE, INC.
Underwriting Agreement • December 12th, 2022 • Biolase, Inc • Dental equipment & supplies • New York

Biolase, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters” or each, an “Underwriter”) an aggregate of (x) [•] units of the Company (each a “Unit” and collectively, the “Units”), with each Unit consisting of (i) one share (each a “Firm Share” and collectively, the “Firm Share”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) and (ii) one common stock purchase warrant of the Company (each a “Firm Warrant” and collectively, the “Firm Warrants”), with each Firm Warrant exercisable to purchase one share of Common Stock (the “Firm Warrant Shares”), at an exercise price of $[•] per share, subject to adjustment therein, and (y) [•] pre-funded units of the Company (each a “Pre-Funded Unit” and collectively, the “Pre-Funded Units”), with each Pre-Funded Unit consisting of one pre-funded common stock purchase warrant of the Company (each a “Firm Pre-Funded Warrant” an

2,350,000 Shares1 Aziyo Biologics, Inc. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • December 5th, 2022 • Aziyo Biologics, Inc. • Biological products, (no disgnostic substances) • New York

Aziyo Biologics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 2,350,000 shares (the “Firm Shares”) of Class A common stock, $0.001 par value per share (the “Class A common stock” and together with the Company’s Class B common stock, $0.001 par value per share, the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 352,500 additional shares of Class A common stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”

2,275,000 Shares OrthoPediatrics Corp. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • August 12th, 2022 • Orthopediatrics Corp • Surgical & medical instruments & apparatus • New York

OrthoPediatrics Corp., a Delaware corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of (i) 750,000 shares (the “Firm Shares”) of Common Stock, $0.00025 par value per share (the “Common Stock”) and (ii) 1,525,000 pre-funded warrants to purchase up to an aggregate of 1,525,000 shares of Common Stock (the “Pre-Funded Warrants”) at an exercise price of $0.00025 per share, of the Company. The Company has also granted to the several Underwriters an option to purchase up to 341,250 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Shares.” The shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants are herein referred to as the “Warrant Shares.” The Shares, the Warrant Shares and the Pre-Funded War

] Shares Connexa Sports Technologies Inc. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • June 14th, 2022 • Connexa Sports Technologies Inc. • Sporting & athletic goods, nec • New York

Connexa Sports Technologies Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions of this underwriting agreement (this “Agreement”), to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ ] shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the Underwriters an option to purchase up to [ ] additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares are collectively referred to herein as the “Securities”.

4,700,000 Shares1 Lantronix, Inc. Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • November 22nd, 2021 • Lantronix Inc • Computer communications equipment • New York

Lantronix, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,700,000 shares (the “Firm Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. TL Investment GmbH, a German limited liability company (the “Selling Stockholder”), has also granted to the Underwriters an option to purchase up to 705,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”

3,750,000 Shares1 NEUROONE MEDICAL TECHNOLOGIES CORPORATION Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • October 14th, 2021 • NEUROONE MEDICAL TECHNOLOGIES Corp • Surgical & medical instruments & apparatus • New York

NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”) proposes to sell to Craig-Hallum Capital Group LLC (the “Underwriter”) an aggregate of 3,750,000 shares (the “Firm Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company has also granted to the Underwriter an option to purchase up to 562,500 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”

1,400,000 Shares1 Jerash Holdings (US), Inc. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • October 4th, 2021 • Jerash Holdings (US), Inc. • Apparel & other finishd prods of fabrics & similar matl • New York

Jerash Holdings (US), Inc., a Delaware corporation (the “Company”), and Merlotte Enterprise Limited (the “Selling Stockholder”) propose to sell, acting severally and not jointly, to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,400,000 shares (the “Firm Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company and the Selling Stockholder, acting severally and not jointly, have also granted to the Underwriters an option to purchase up to 210,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.” The aggregate number of Firm Shares that the Company and the Selling Stockholder are each selling is listed in Schedules I and II hereto.

4,720,000 Shares PLBY Group, Inc. Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • June 14th, 2021 • PLBY Group, Inc. • Retail-miscellaneous retail • New York

PLBY Group, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,720,000 shares (the “Firm Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also proposes to grant to the several Underwriters an option to purchase up to 708,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3(b) hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”

●] Shares PLBY Group, Inc. Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • June 7th, 2021 • PLBY Group, Inc. • Retail-miscellaneous retail • New York

PLBY Group, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also proposes to grant to the several Underwriters an option to purchase up to [●] additional shares of Common Stock on the terms and for the purposes set forth in Section 3(b) hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”

●] Shares1 Anebulo Pharmaceuticals, Inc. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • April 26th, 2021 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also proposes to grant to the several Underwriters an option to purchase up to [●] additional shares of Common Stock on the terms and for the purposes set forth in Section 3(b) hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”

2,647,059 Shares1 Inotiv, Inc. Common Shares UNDERWRITING AGREEMENT
Underwriting Agreement • April 21st, 2021 • Inotiv, Inc. • Services-commercial physical & biological research • New York

Inotiv, Inc., an Indiana corporation (the “Company”), proposes to sell to Colliers Securities LLC (“you” or the “Underwriter”) an aggregate of 2,647,059 common shares (the “Firm Shares”) of the Company (the “Common Shares”). The Firm Shares consist of authorized but unissued Common Shares to be issued and sold by the Company. The Company also has granted to the Underwriter an option to purchase up to 397,058 additional Common Shares on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”

6,015,000 Shares1 Full House Resorts, Inc. Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • March 29th, 2021 • Full House Resorts Inc • Hotels & motels • New York

Full House Resorts, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 6,015,000 shares (the “Firm Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the Underwriters an option to purchase up to 902,250 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”

11,111,111 Shares1 Phunware, Inc. Common Stock, $0.0001 par value per share UNDERWRITING AGREEMENT
Underwriting Agreement • February 16th, 2021 • Phunware, Inc. • Services-computer processing & data preparation • New York

Phunware, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 11,111,111 shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the Underwriters an option to purchase up to 1,666,666 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities”. Notwithstanding anything to the contrary herein, the number of shares of the Securities shall not exceed 19.9% of the issued and outstanding securities prior to the offering.

1,783,500 Shares1 Limbach Holdings, Inc. Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • February 10th, 2021 • Limbach Holdings, Inc. • Construction - special trade contractors • New York

Limbach Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,783,500 shares (the “Firm Shares”) of Common Stock, par value $0.0001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the Underwriters an option to purchase up to 267,525 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”

5,327,773 Shares1 REKOR SYSTEMS, INC. Common Stock, $0.0001 par value per share UNDERWRITING AGREEMENT
Underwriting Agreement • February 9th, 2021 • Rekor Systems, Inc. • Communications equipment, nec • New York

Rekor Systems, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,327,773 shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the Underwriters an option to purchase up to 799,166 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (the “Agreement”) are herein collectively called the “Securities”.

UNDERWRITING AGREEMENT
Underwriting Agreement • October 6th, 2020 • Heritage Global Inc. • Services-business services, nec • New York

Heritage Global Inc., a Florida corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,750,000 shares (the “Firm Shares”) of Common Stock, $0.01 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also has granted to the Underwriters an option to purchase up to 712,500 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Agreement are herein collectively called the “Securities”.

4,800,000 Shares PROCESSA PHARMACEUTICALS, INC. Common Stock, $0.0001 Par Value per Share UNDERWRITING AGREEMENT
Underwriting Agreement • October 6th, 2020 • Processa Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
·] Shares1 Aziyo Biologics, Inc. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • September 30th, 2020 • Aziyo Biologics, Inc. • Biological products, (no disgnostic substances) • New York

Aziyo Biologics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [·] shares (the “Firm Shares”) of either Class A common stock, $0.001 par value per share (the “Class A common stock”), of the Company or, to the extent shares are purchased by entities affiliated with Deerfield Private Design Fund III, L.P., Class B common stock, $0.001 par value per share (the “Class B common stock” and, together with the Class A common stock, the “Common Stock”), of the Company. The Firm Shares consist of [·] authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to [·] additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (

AutoNDA by SimpleDocs
●] Shares PROCESSA PHARMACEUTICALS, INC. Common Stock, $0.0001 Par Value per Share UNDERWRITING AGREEMENT
Underwriting Agreement • September 17th, 2020 • Processa Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

Processa Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] authorized but unissued shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Company also proposes to grant to the several Underwriters an option to purchase up to [●] additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”

1,600,000 Shares OrthoPediatrics Corp. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • June 18th, 2020 • Orthopediatrics Corp • Surgical & medical instruments & apparatus • New York

OrthoPediatrics Corp., a Delaware corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,600,000 shares (the “Firm Shares”) of Common Stock, $0.00025 par value per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 240,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”

11,797,752 Shares Warrants to Purchase 8,848,314 Shares CONTRAFECT CORPORATION Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • May 27th, 2020 • CONTRAFECT Corp • Pharmaceutical preparations • New York

ContraFect Corporation, a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) (i) an aggregate of 11,797,752 shares (the “Shares”) of common stock, $0.0001 par value per share (the “Common Stock”), of the Company and (ii) warrants to purchase up to an aggregate of 8,848,314 shares of Common Stock on the terms and conditions set forth in the form of warrant attached as Exhibit A hereto (the “Warrants”). Each Share is being sold together with a Warrant to purchase 0.75 shares of Common Stock at an exercise price of $4.90 per whole share of Common Stock. The aggregate number of shares of Common Stock underlying the Warrants are referred to herein as the “Warrant Shares.” The Shares, Warrants and Warrant Shares are collectively referred to in this Agreement as the “Securities.”

3,191,489 Shares ROCKWELL MEDICAL, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • February 6th, 2020 • Rockwell Medical, Inc. • Electromedical & electrotherapeutic apparatus • New York

Rockwell Medical, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 3,191,489 shares (the “Firm Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to 478,723 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”

●] Shares[1] Allied Esports Entertainment, Inc. Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • February 3rd, 2020 • Allied Esports Entertainment, Inc. • Services-amusement & recreation services • New York
UNDERWRITING AGREEMENT
Underwriting Agreement • January 28th, 2020 • Itamar Medical Ltd. • Surgical & medical instruments & apparatus • New York
1,570,000 Shares OrthoPediatrics Corp. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • December 12th, 2019 • Orthopediatrics Corp • Surgical & medical instruments & apparatus • New York

OrthoPediatrics Corp., a Delaware corporation (the “Company”), and the stockholders of the Company listed in Schedule I hereto (the “Selling Stockholders”) severally propose to sell to the several Underwriters named in Schedule II hereto (the “Underwriters”) an aggregate of 1,570,000 shares (the “Firm Shares”) of Common Stock, $0.00025 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 1,520,000 authorized but unissued shares of Common Stock to be issued and sold by the Company and 50,000 outstanding shares of Common Stock to be sold by the Selling Stockholders. The Company has also granted to the several Underwriters an option to purchase up to 235,500 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”

2,103,702 Shares OPTIMIZERX CORPORATION Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • December 20th, 2018 • WPP PLC • Services-advertising agencies • New York
2,103,702 Shares OptimizeRx Corporation Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • December 18th, 2018 • OptimizeRx Corp • Services-business services, nec • New York

The selling shareholder named in Schedule I hereto (the “Selling Shareholder”) proposes to sell to the several Underwriters named in Schedule II hereto (the “Underwriters”) an aggregate of 2,103,702 shares (the “Firm Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), of OptimizeRx Corporation, a Nevada corporation (the “Company”). The Company has also granted to the several Underwriters an option to purchase up to 315,555 additional shares of Common Stock on the terms and for the purposes set forth in Section 4 hereof (collectively, the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”

UNDERWRITING AGREEMENT
Underwriting Agreement • December 11th, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • New York
1,500,000 Shares OrthoPediatrics Corp. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • December 7th, 2018 • Orthopediatrics Corp • Surgical & medical instruments & apparatus • New York
UNDERWRITING AGREEMENT
Underwriting Agreement • November 27th, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • New York

DiaMedica Therapeutics Inc. (the “Company”), a business corporation governed by the Canada Business Corporations Act (the “Corporations Act”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] (the “Firm Shares”) authorized but unissued voting common shares, without par value (the “Common Shares”), of the Company. The Company also proposes to grant to the several Underwriters an option to purchase up to an additional [●] Common Shares on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”

1,205,000 Shares of Common Stock1 ENDRA LIFE SCIENCES INC. UNDERWRITING AGREEMENT
Underwriting Agreement • November 13th, 2018 • ENDRA Life Sciences Inc. • Electromedical & electrotherapeutic apparatus • New York

ENDRA Life Sciences Inc., a Delaware corporation (the “Company”), proposes to sell to National Securities Corporation, a Washington corporation (the “Underwriter” or “you”), an aggregate of 1,205,000 authorized but unissued shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Firm Shares”) pursuant to this Underwriting Agreement (the “Agreement”). The Company also has granted to the Underwriter an option to purchase up to 180,750 additional shares of Common Stock (the “Option Shares”, and together with the Firm Shares, the “Securities”).

Time is Money Join Law Insider Premium to draft better contracts faster.